FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890762676> ?p ?o ?g. }

• W2890762676 endingPage "TPS3131" @default.
• W2890762676 startingPage "TPS3131" @default.
• W2890762676 abstract "TPS3131 Background: Birinapant is a bivalent SMAC mimetic with activity against multiple members of the inhibitor of apoptosis protein (IAP) family including cIAP1 and has demonstrated tolerability with robust and durable target engagement in advanced cancers. Synergistic effects of combining birinapant with immune checkpoint inhibitors have been demonstrated in preclinical models, consistent with the reported role of cIAP1 in tumor cells and immune cells (Beug et al., 2017). Based on these observations, a phase 1/2 trial with birinapant and pembrolizumab has been initiated (NCT02587962). Methods: In the dose escalation part of this multi-center phase 1/2 study, patients > 18 years with advanced solid tumors without further suitable standard therapeutic options are eligible for inclusion. The primary objective is to determine the safety and tolerability of the recommended phase 2 dose (RP2D) of birinapant in combination with pembrolizumab using a standard 3+3 design. The secondary objective is to assess efficacy by RECIST 1.1. The doses of birinapant to be evaluated are 5.6, 11, 17 and 22 mg/m2 IV on day 1 and 8 in addition to pembrolizumab 200 mg on day 1 in a 21-day cycle. RP2D will be proposed by the safety review committee. The phase 2 part plans to include 111 patients. The primary objective is to assess the clinical activity of birinapant and pembrolizumab, measured as ORR by RECIST in separate cohorts of microsatellite stable colorectal (N = 28), ovarian (N = 27) and cervical cancer (N = 26). Simon’s two-stage design yields a type I error rate of 0.05 and statistical power of 0.80 for each of the three cohorts using a one-sided test based on true response rates of 20% (colorectal cancer), 25% (ovarian cancer) and 30% (cervical cancer). The study will also evaluate an exploratory cohort consisting of five patients each with small cell lung cancer, cholangiocarcinoma, gastroesophageal carcinoma, mesothelioma, head and neck squamous cell carcinoma (check-point inhibitor-naïve and experienced). The phase 2 secondary objectives are safety and tolerability, tumor response, progression-free and overall survival. Exploratory objectives will assess tumor response by iRECIST, pharmacokinetics, pharmacodynamics and predictive biomarkers. Clinical trial information: NCT02587962." @default.
• W2890762676 created "2018-09-27" @default.
• W2890762676 creator A5002714921 @default.
• W2890762676 creator A5003308209 @default.
• W2890762676 creator A5016917647 @default.
• W2890762676 creator A5026638826 @default.
• W2890762676 creator A5034716213 @default.
• W2890762676 creator A5068831487 @default.
• W2890762676 creator A5083650154 @default.
• W2890762676 creator A5086547100 @default.
• W2890762676 date "2018-05-20" @default.
• W2890762676 modified "2023-10-16" @default.
• W2890762676 title "A phase 1/2 study with birinapant in combination with pembrolizumab." @default.
• W2890762676 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.tps3131" @default.
• W2890762676 hasPublicationYear "2018" @default.
• W2890762676 type Work @default.
• W2890762676 sameAs 2890762676 @default.
• W2890762676 citedByCount "4" @default.
• W2890762676 countsByYear W28907626762019 @default.
• W2890762676 countsByYear W28907626762020 @default.
• W2890762676 countsByYear W28907626762021 @default.
• W2890762676 countsByYear W28907626762023 @default.
• W2890762676 crossrefType "journal-article" @default.
• W2890762676 hasAuthorship W2890762676A5002714921 @default.
• W2890762676 hasAuthorship W2890762676A5003308209 @default.
• W2890762676 hasAuthorship W2890762676A5016917647 @default.
• W2890762676 hasAuthorship W2890762676A5026638826 @default.
• W2890762676 hasAuthorship W2890762676A5034716213 @default.
• W2890762676 hasAuthorship W2890762676A5068831487 @default.
• W2890762676 hasAuthorship W2890762676A5083650154 @default.
• W2890762676 hasAuthorship W2890762676A5086547100 @default.
• W2890762676 hasConcept C121608353 @default.
• W2890762676 hasConcept C126322002 @default.
• W2890762676 hasConcept C143998085 @default.
• W2890762676 hasConcept C197934379 @default.
• W2890762676 hasConcept C2777701055 @default.
• W2890762676 hasConcept C2778375690 @default.
• W2890762676 hasConcept C2779984678 @default.
• W2890762676 hasConcept C2780057760 @default.
• W2890762676 hasConcept C31760486 @default.
• W2890762676 hasConcept C535046627 @default.
• W2890762676 hasConcept C71924100 @default.
• W2890762676 hasConceptScore W2890762676C121608353 @default.
• W2890762676 hasConceptScore W2890762676C126322002 @default.
• W2890762676 hasConceptScore W2890762676C143998085 @default.
• W2890762676 hasConceptScore W2890762676C197934379 @default.
• W2890762676 hasConceptScore W2890762676C2777701055 @default.
• W2890762676 hasConceptScore W2890762676C2778375690 @default.
• W2890762676 hasConceptScore W2890762676C2779984678 @default.
• W2890762676 hasConceptScore W2890762676C2780057760 @default.
• W2890762676 hasConceptScore W2890762676C31760486 @default.
• W2890762676 hasConceptScore W2890762676C535046627 @default.
• W2890762676 hasConceptScore W2890762676C71924100 @default.
• W2890762676 hasIssue "15_suppl" @default.
• W2890762676 hasLocation W28907626761 @default.
• W2890762676 hasOpenAccess W2890762676 @default.
• W2890762676 hasPrimaryLocation W28907626761 @default.
• W2890762676 hasRelatedWork W2107697672 @default.
• W2890762676 hasRelatedWork W2406666623 @default.
• W2890762676 hasRelatedWork W2738397398 @default.
• W2890762676 hasRelatedWork W2981540799 @default.
• W2890762676 hasRelatedWork W3177224496 @default.
• W2890762676 hasRelatedWork W4210362744 @default.
• W2890762676 hasRelatedWork W4221049467 @default.
• W2890762676 hasRelatedWork W4286293786 @default.
• W2890762676 hasRelatedWork W4367668180 @default.
• W2890762676 hasRelatedWork W4384922324 @default.
• W2890762676 hasVolume "36" @default.
• W2890762676 isParatext "false" @default.
• W2890762676 isRetracted "false" @default.
• W2890762676 magId "2890762676" @default.
• W2890762676 workType "article" @default.